Fluidigm is the leader in mass cytometry and microfluidics

4 de mar. de 2021

Greetings

Summary:
Fundamental Analysis:

• Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative.Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies
  
  • Fluidigm is a leader in mass cytometry. According to market research and Fluidigm, the mass cytometry market reached 2.7 billion with CAGR at 26% by 2025.
    
    • The Biden administration plans to spend about $ 1.6 billion on expanding Covid-19 testing programs.
      
      • Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China.According to company and third-party estimates, the addressable market for flow cytometry analysis in blood cancer in China is approximately $100 million for 2021–2023, and is growing at a double-digit rate.
        
        • The company shows stable revenue growth from year to year.
          
          Technical analysis:
          • From March 2020 to the end of September 2020, the 5th wave movement was completed.After that, a correction began, namely a double three, consisting of 2 zigzags.
            
            • At the moment, the company's shares are in the oversold zone according to the RSI indicator.
              
              • The company has several open gaps, namely in the following areas: $ 10-11, $ 15-19, $ 30-36 per share.
                
                • At the moment, the company's shares are at a strong support level.
                  
                  Disclosure: I am/we are long FLDM.
                  
                  I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.